• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen 2nd-quarter profit tops Street view, raises 2016 forecast

July 27, 2016 By drugdelivery

Amgen(Reuters) – Amgen (NSDQ:AMGN) on Wednesday reported higher-than-expected 2nd-quarter profit on increased sales of its blockbuster rheumatoid arthritis drug Enbrel and newer medicines, and the company again raised its full-year forecast.

The forecast appeared to signal management’s confidence in the 2nd half of the year.

The company is on track to meet or exceed its long-term objectives,” Chief Executive Robert Bradaway said in a statement.

Amgen said it now expects 2016 adjusted earnings per share of $11.10 to $11.40, up from its prior view of $10.85 to $11.20. Its midpoint is above of Wall Street estimates of $11.18 for the year.

The company, which significantly increased its earnings forecast after the 1st quarter, also raised its full-year revenue outlook and now expects $22.5 billion to $22.8 billion, up from $22.2 billion to $22.6 billion.

Excluding special items, Amgen had adjusted earnings of $2.84 per share, topping analysts’ average expectations by 10 cents, according to Thomson Reuters I/B/E/S.

Revenue for the quarter rose 6% to $5.7 billion, exceeding Wall Street estimates of about $5.6 billion, led by Enbrel, whose sales rose 10% to $1.48 billion, helped by another round of price increases.

The world’s largest biotechnology company by market value said net profit rose to $1.87 billion, or $2.47 per share, from $1.65 billion, or $2.15 per share, a year ago.

Sales of the osteoporosis drug Prolia rose 30% to $441 million, sailing past Wall Street estimates of about $388 million. Sales of the multiple myeloma drug Kyprolis jumped 45% to $172 million, shy of analysts’ consensus forecast of about $185 million.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Amgen

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS